ClinicalTrials.gg
Active, not recruitingNCT04838444Updated Jul 9, 2026Results posted

Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553)

A Phase 3 interventional study of VLA1553 in Chikungunya Virus Infection, sponsored by Valneva Austria GmbH. Active, not recruiting at 10 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Valneva Austria GmbH (part of Valneva) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Chikungunya Fever by Valneva — 2 open to participants now, 5 under way, 1 of them phase 3. Chikungunya Fever · Valneva.

Started
2021
with 1 other
Phase 3
5 of 11
none open now
Registered
4th of 11
by date

Among the 11 studies in Chikungunya Fever by Valneva, this one is one of 2 that started in 2021, is one of 5 in phase 3, and was the 4th registered.

Chikungunya Fever

88 studies on the registry are indexed under Chikungunya Fever; 21 are open to participants now.

Browse Chikungunya Fever studies →

Open to participants now

2 of the 11 studies in Chikungunya Fever by Valneva are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 8 Chikungunya Fever studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Chikungunya Fever by Valneva, or all of them as a file.
02

Study summary

In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety will be evaluated in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724).

Read the detailed description

In this open-label Phase 3b, single arm trial, persistence of antibodies and long term safety in up to 375 participants rolled over from trial VLA1553-301 (NCT number: NCT04546724)

These participants will have annual follow-up visits at Months 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 after immunization. The primary objective of this trial will be to evaluate persistence of antibodies annually from 1 to 10 years after the single immunization with VLA1553. The secondary objective is to evaluate long-term safety 6 months to 2 years after the single immunization with VLA1553.

03

Conditions studied

  • Chikungunya Virus Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individual participated in the VLA1553-301 clinical trial;
  • Participant has an understanding of the trial and its procedures, agrees to its provisions, and voluntarily gives written prior to any trial-related procedures;
  • Participant had immunogenicity blood samples taken at baseline (Visit 1) and either Day 29 (Visit 3), Day 85 (Visit 4) or Day 180 (Visit 5) in Trial VLA1553-301 and was negative for neutralizing antibodies at baseline

Exclusion criteria

Exclusion Criteria:

  • Participant presents with clinical conditions representing a to blood draws;
  • Participant has donated blood or use of blood products prior 30 days of immunogenicity sampling;
  • Participant has received an active drug with potential action or drug or device within a period of 30 days prior a trial visit;
  • Participant has a known or suspected problem with alcohol or drug abuse as determined by the Investigator;
  • Participant has any condition that, in the opinion of the Investigator, may compromise the participant's well-being, might interfere with evaluation of trial endpoints, or would limit the participant's ability to complete the trial;
  • Participant is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities);
  • Participant is a member of the team conducting the trial or in a dependent relationship with one of the trial team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    VLA1553

    Biological: VLA1553

Interventions

  • BiologicalVLA1553

    Trial participants previously vaccinated with VLA1553 in trial VLA1553-301 will be followed up for safety and immunogenicity.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Seroresponse Levels Post-vaccination. (Defined as µPRNT50 ≥150)

    Data for Visit 1 - Day 1 are collected from Trial VLA1553-301

    Time frame: Year 2

Secondary outcomes

  1. Frequency of Any Serious Adverse Event (SAE)

    Time frame: until Year 2

  2. Relatedness of Any Serious Adverse Event (SAE)

    Time frame: until Year 2

  3. Immune Response as Measured by CHIKV-specific Neutralizing Antibody Titers Post-vaccination

    Time frame: until Year 10

  4. Proportion of Participants With Seroconversion

    Time frame: until Year 10

  5. Fold Increase of CHIKV-specific Neutralizing Antibody Titers Post-vaccination as Compared to Baseline (i.e. at Start of Trial VLA1553-301)

    Time frame: until Year 10

  6. Proportion of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold Increase in CHIKV-specific Neutralizing Antibody Titer Compared to Baseline

    Time frame: until Year 10

07

Results

Posted Jul 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneVLA1553
Started363
Completed317
Not completed46

Outcome measures

PrimaryProportion of Participants With Seroresponse Levels Post-vaccination. (Defined as µPRNT50 ≥150)

Data for Visit 1 - Day 1 are collected from Trial VLA1553-301

Time frame:
Year 2
Reported as:
Number · percentage of participants with SRR
Proportion of Participants With Seroresponse Levels Post-vaccination. (Defined as µPRNT50 ≥150)
percentage of participants with SRRVLA1553: 18 - 64 YearsVLA1553: >=65 Years
Visit 1 - Day 10 (0.0 to 0.0)0 (0.0 to 0.0)
Visit 1 - Year 199.4 (96.5 to 100.0)100 (87.2 to 100.0)
Visit 2 - Year 297 (93.9 to 98.8)97.6 (87.4 to 99.9)
SecondaryFrequency of Any Serious Adverse Event (SAE)
Time frame:
until Year 2

Results for this outcome have not been posted.

SecondaryRelatedness of Any Serious Adverse Event (SAE)
Time frame:
until Year 2

Results for this outcome have not been posted.

SecondaryImmune Response as Measured by CHIKV-specific Neutralizing Antibody Titers Post-vaccination
Time frame:
until Year 10

Results for this outcome have not been posted.

SecondaryProportion of Participants With Seroconversion
Time frame:
until Year 10

Results for this outcome have not been posted.

SecondaryFold Increase of CHIKV-specific Neutralizing Antibody Titers Post-vaccination as Compared to Baseline (i.e. at Start of Trial VLA1553-301)
Time frame:
until Year 10

Results for this outcome have not been posted.

SecondaryProportion of Participants Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold Increase in CHIKV-specific Neutralizing Antibody Titer Compared to Baseline
Time frame:
until Year 10

Results for this outcome have not been posted.

Adverse events

Collected over Long-term safety (i.e. Serious Adverse Events [SAEs]) was collected 6 months to 2 years after the single immunization with VLA1553.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VLA1553: 18 - 64 Years1/310 (0.3%)6/310 (1.9%)—
VLA1553: >=65 Years0/53 (0%)2/53 (3.8%)—
Most frequent serious events
Most frequent serious events
EventVLA1553: 18 - 64 YearsVLA1553: >=65 Years
Intracranial aneurysmNervous system disorders0/3101/53
Coronary artery diseaseCardiac disorders0/3101/53
Gun shot woundInjury, poisoning and procedural complications1/3100/53
OverdoseInjury, poisoning and procedural complications1/3100/53
Pelvic fractureInjury, poisoning and procedural complications1/3100/53
SeizureNervous system disorders1/3100/53
Abdominal pain upperGastrointestinal disorders1/3100/53
CholecystitisHepatobiliary disorders1/3100/53

Baseline characteristics

The Whole Sample Population (WSP) contains: * All participants who entered into the VLA1553-303. * Received VLA1553 in trial VLA1553-301. * Had a post-baseline immunogenicity sample available from the VLA1553-301. * Participants need a Visit 1 record on VLA1553-303 to be included in the WS population. This will include all participants who had an informed consent in VLA1553-303 and met all inclusion/exclusion criteria to be enrolled into the trial and had a Visit 1 record in VLA1553-303.

Age, Customized
Age, Customized(years)VLA1553: 18 - 64 YearsVLA1553: >=65 YearsTotal
Mean44.1 ± 12.0268.7 ± 3.3747.7 ± 14.15
Sex: Female, Male
Sex: Female, Male(Participants)VLA1553: 18 - 64 YearsVLA1553: >=65 YearsTotal
Female17730207
Male13323156
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VLA1553: 18 - 64 YearsVLA1553: >=65 YearsTotal
Hispanic or Latino40343
Not Hispanic or Latino26549314
Unknown or Not Reported516
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VLA1553: 18 - 64 YearsVLA1553: >=65 YearsTotal
American Indian or Alaska Native202
Asian606
Native Hawaiian or Other Pacific Islander213
Black or African American44852
White23743280
Other19120
08

Study locations

10 sites
09

References and documents

Publications

  • McMahon R, Toepfer S, Sattler N, Schneider M, Narciso-Abraham M, Hadl S, Hochreiter R, Kosulin K, Mader R, Zoihsl O, Wressnigg N, Dubischar K, Buerger V, Eder-Lingelbach S, Jaramillo JC. Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study. Lancet Infect Dis. 2024 Dec;24(12):1383-1392. doi: 10.1016/S1473-3099(24)00357-8. Epub 2024 Aug 12. PubMed 39146946 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After trial completion, Valneva may provide access to individual de-identified participant data and related trial documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Trial Report (CTR)) upon request from qualified researchers, and subject to Valneva's review and approval.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Mar 2023, 23 months.

Results were first posted in Jul 2026, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2021
First posted
Apr 9, 2021
StartActual
Apr 2, 2021
Primary completionActual
Mar 3, 2023
CompletionEst.
May 2031
Results first posted
Jul 9, 2026
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04838444
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
Apr 2, 2021
Primary completion
Mar 3, 2023
Completion
May 2031 (estimated)
Results posted
Jul 9, 2026
Last update
Jul 9, 2026

Study contacts

Valneva Clinical Development
study chair · Valneva Austria GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chikungunya vaccine

Start the discussion